BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-881 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-881\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06076642-11365@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:TAK-881: Phase 3 readout est. (NCT06076642)
DESCRIPTION:TAK-881\, phase 3\, Primary Immunodeficiency.\nStudy: A Study A
 bout the Long-Term Safety of TAK-881 in People With Primary Immunodeficien
 cy Diseases\nEstimated primary completion: 16 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06076642
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747351-11365@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20280625
DTEND;VALUE=DATE:20280626
SUMMARY:TAK-881: Phase 3 readout est. (NCT06747351)
DESCRIPTION:TAK-881\, phase 3.\nStudy: A Study to Compare TAK-881 and HYQVI
 A in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  (CIDP)\nEstimated primary completion: 25 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06747351
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
